Metabolic Endocrine Education Foundation 638 Lindero Canyon Dr #380 Oak Park, CA 91377

NONPROFIT ORG US POSTAGE PAID VAN NUYS, CA PERMIT # 659 CME Symposium IN ASSOCIATION WITH THE



EARN CME

ABIM-MOC CREDITS

1.25

Breaking New Ground in Heart Failure Treatment

Friday December 8, 2023 6:15pm – 7:30pm PST Hilton Universal City Hotel Los Angeles, California

This is a CME Symposium Supported by an Educational Grant from Lexicon Pharmaceutical Free for all 21st WCIRDC Attendees | Register Online: wcir.org/registration All Content available ON DEMAND for ONE YEAR following the meeting

Register online: www.WCIR.org/CMEdinner Please choose CME Dinner Symposium from the Menu



Administered By: 🛛 👌





Breaking New Ground in Heart Failure Treatment

6:15 pm – 7:30 pm Dinner CME Symposium Supp		rted by L exicon Pharmaceuticals
	Breaking New Ground in Heart Failure Treatment Chairs: Matthew Budoff, MD • Yehuda Handelsman, MD	
6:15 pm	Introduction & Pre CME Questions	Yehuda Handelsman, MD
6:25 pm	Prevalence, Pathophysiology and Morbidities of Heart Failure	Matthew J. Budoff, MD
6:40 pm	Contemporary Approach to Management of Heart Failure	Stephen J. Greene, MD
6:55 pm	Sotagliflozin: The Next Generation of Heart Failure Management	Darren McGuire, MD, MHSc
7:10 pm	Panel Discussion, Q&A, and Post-CME: Advancing the Care of Heart Failure- Relationship to CKD	
Panel:	Matthew J. Budoff, MD, Stephen J. Greene, MD, Darren McGuire, MD, MHSc, Matthew R. Weir, MD	
Moderator	: Yehuda Handelsman, MD	
7:25 pm	Post-CME Questions & Concluding Remarks	
7:30 pm	Adjourn	

Program Description

This CME satellite symposium will explore the changing landscape of therapies for patients with HF with or without diabetes. The program will address the gaps in physicians' knowledge of the Epidemiology & and pathophysiology of heart failure, the new 2022 ACC/AHA/HFSA Ejection Fraction based Heart Failure management guidelines, and the emerging role of sotagliflozin an SGLT2/1- in heart Failure patients with and without T2D, CKD and other CV risks.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

- Discuss the epidemiology of HF
- Understand the Pathophysiology of HF
- Be Aware of the Ejection Fraction based 2022 treatment Guidelines for HF
- Describe the Potential Mode of action of SGLT2 & SGLT1 inhibitors.
- Develop management strategies for patients with HF including those with DM & CKD

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, nephrologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of people with Heart failure or Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.



Matthew J. Budoff, MD, Chair ACC, FAHA

ACC, FAHA Professor of Medicine David Geffen School of Medicine at UCLA Endowed Chair of Preventive Cardiology Program Director, Director of Cardiac CT Lundquist Institute Harbor-UCLA Medical Center, Division of Cardiology Los Angeles, California



Stephen J. Greene, MD Assistant Professor, Division of Cardiology Advanced Heart Failure & Transplantation Duke University Medical Center Duke Clinical Research Institute Durham, North Carolina



Matthew R. Weir, MD Professor and Chief Division of Nephrology Department of Medicine University of Maryland School of Medicine Baltimore, Maryland

FACULTY



Yehuda Handelsman, MD, Chair FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator The Metabolic Institute of America Chair Scientific Advisory Board DCMi- Diabetes CardioRenal & Metabolism Institute Chair & Program Director 21st WCIRDC Tarzana, California



Darren McGuire, MD, MHSc

Distinguished Teaching Professor of Medicine with Tenure Jere H. Mitchell, M.D. Distinguished Chair in Cardiovascular Science Division of Cardiology; Department of Internal Medicine University of Texas Southwestern Medical Center Lead Physician, Parkland Health Cardiology Clinics Deputy Editor, Circulation Dallas, Texas

CME Supported Symposium

This CME symposium is FREE for 21st WCIRDC attendees and will stay on-demand for ONE year following the meeting. Learn more: Learn more:WCIR.ORG/CMEsymposium

To register for the entire 21st WCIRDC meeting please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc., designated this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: info@tmioa.com or 818.342.1889

This is a CME Program Supported by an Educational Grant from Lexicon Pharmaceuticals